Legal expert in health care, partner, and cochair of the health care coverage and reimbursement practice at Foley Hoag LLP, Ross Margulies discusses his excitement and expectations as a featured speaker at the upcoming 2024 AMCP Annual Conference.
The Academy of Managed Care Pharmacy (AMCP) is hosting its annual conference in New Orleans this year from April 15-18, and will be attracting over 4000 attendees.
One of the featured speakers is Ross Margulies, a health care attorney and partner at Foley Hoag LLP. Margulies will be focusing on health care reform and its impact on pharmacy benefit managers (PBMs). In this interview, he shares his expectations for the conference and the key takeaways he hopes attendees will gain.
Transcript
What are you looking forward to most at AMCP?
I've been to AMCP conferences many times over the last 6 or 7 years probably. Frankly, what I love about AMCP is it's one of the few forums where you get together different stakeholders, pharmacies, managed care pharmacies, community pharmacies, PBMs, manufacturers, and you talk about some of the tough issues. I'm talking about one of them, which is PBM reform. You know, it's pretty rare these days that you get diverse perspectives, and I honestly think a lot of really interesting conversations happen because of that.
What are you hoping attendees can take away from the meeting this year?
With respect to PBM reforms, I'd like my attendees to know what Congress is considering because it's filled with a lot of jargon, it’s very confusing. But I think the chance that there is going to be some type of PBM reform is pretty likely. No matter where you are on the drug supply chain, understanding what those provisions are and how they impact you is going to be really necessary, so that's my goal.
AI, GLP-1s Among Topics to Be Discussed During ASPC Annual Meeting
July 28th 2025The American Society for Preventive Cardiology (ASPC) Congress on Cardiovascular Disease Prevention features multiple sessions on different methods of treating and preventing cardiovascular disease, including through the use of artificial intelligence (AI) and glucagon-like peptide-1 (GLP-1) receptor agonists.
Read More
Across 8 Trials, Ruxolitinib Cream Shows Favorable Safety in Pediatric AD
July 25th 2025A poster at the Society for Pediatric Dermatology Annual Meeting presented an integrated safety analysis showing rare or no serious adverse events linked to topical Janus kinase inhibitor use in children with atopic dermatitis (AD).
Read More